• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ACRS

ACRS

Aclaris Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD4.42

-0.21 (-4.54%)

Rating:C

Company Profile

CEO

Neal S. Walker

IPO Date

2015-10-06

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$4.63

Prev. Close

$4.63

Day Low

$4.41

Day High

$4.66

52W Low

$1.34

52W High

$5.15

Market Cap

$0.53B

Volume

1.56M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

44.7%

Avg Negative

11.1%

Avg Neutral

44.2%

News Feed

Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zacks Investment Research·7/30/2021·↑ positive

Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate

Zacks Investment Research·6/9/2021·↑ positive

RMED, HOOK, JZXN, ACRS, OPRA, CVAC Stock Prices Fall Intraday

Pulse2·6/8/2021·↓ negative

Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure

Benzinga·6/8/2021·↑ positive

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research·5/7/2021·↑ positive

Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update

GlobeNewsWire·5/7/2021·↑ positive

Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon

Seeking Alpha·3/2/2021·↑ positive

Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA

Zacks Investment Research·1/20/2021·↑ positive

Aclaris Announces Pricing of Public Offering of Common Stock

GlobeNewsWire·1/20/2021·↑ positive

ACRS Stock Price Increases 220.24%: Why It Happened

Pulse2·1/19/2021·↑ positive